/l and renal function tests were normal. At day þ 6, i.v. amikacin (1 g/24 h) was added because of persistence of fever.
At day þ 8, the patient had an episode of atrial fibrillation with a ventricular rate of 190 bpm with secondary hypotension (75/45 mm Hg) and subsequent acute renal failure. The serum creatinine level was 247 mmol/l (2.79 mg/dl) and the patient required dopamine, dobutamine and high doses of furosemide to maintain adequate diuresis.
After 2 days, the patient showed a decreased level of consciousness and myoclonic jerks in the four extremities. He did not respond to verbal stimulus but responded to pain. The remaining neurological examination was normal. Treatment with i.v. phenytoin (100 mg/8 h) was started and amikacin, cloxacillin and cefepime were discontinued. The electroencephalogram (EEG) showed slow base diffuse, bilateral theta-delta activity, with delta waves of 1.5-2 Hz and slight bilateral irritative signs. Cranial computed tomography scan and magnetic resonance images were normal.
At 3 days after the onset of nonconvulsive status epilepticus, the patient recovered consciousness, but the myoclonic jerks and disorientation persisted. After 15 days, a new EEG showed slow activity and a diffuse, bilateral and symmetrical theta base of 5-6 Hz.
After 1 month, the neurological examination was normal and the patient was discharged from hospital. At 7 months after PBSCT, a third relapse of HD occurred involving mesenteric and retroperitoneal lymph nodes and the patient subsequently died.
The patient described here developed nonconvulsive status epilepticus. The most frequent causes of seizures such as infections, cerebrovascular events and metabolic disorders were excluded, leading to the suspicion of a probable drug-related origin. Among the drugs received with potential neurological toxicity, BCNU and etoposide had been administered 11 days before, making this cause highly improbable. Cloxacillin is a potential cause of seizures. However, the main toxicity of cloxacillin is epileptic manifestations with seizures, drowsines and hallucinations, whereas no form of nonconvulsive status epilepticus has been reported. Thus, cefepime was probably the drug that caused the nonconvulsive status epilepticus in this patient.
The level of cefepime in the central nervous system is low under normal conditions, but increases during renal failure due to a competitive inhibition of the antibiotic active transport by organic acids, an increase in blood-brain barrier permeability and a decrease in serum protein binding. 7 The epileptogenic effect of betalactamic antibiotics is the result of a competitive antagonism of the inhibitory neurotransmitter gamma-aminobutyric acid. Cephalosporins have a low degree of epileptogenic activity, but this significantly increases in conditions causing a rise in CSF level, such as either chronic [3] [4] [5] [6] or acute 7 renal failure.
Drug-induced nonconvulsive status epilepticus is a very infrequent complication in patients undergoing SCT. Cefepime should be considered as a possible cause of this complication because it is reversible after discontinuation of the drug and the prognosis is good.
